Articles related to TRANSCATHETER AORTIC-VALVE REPLACEMENT (TAVR)

In this multicenter trial of 901 patients with asymptomatic severe aortic stenosis, early TAVR intervention reduced the composite endpoint of death, stroke, or unplanned cardiovascular hospitalization by 50% compared to clinical surveillance.

Recent findings demonstrate that among patients with small aortic annuli undergoing TAVR, those treated with self-expanding valves experienced significantly lower rates of bioprosthetic-valve dysfunction (9.4%) compared to those with balloon-expandable valves (41.6%), emphasizing the necessity for careful valve selection in clinical practice.